The MESACUP BP230 TEST is a semi-quantitative Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of anti BP230 antibodies in human serum. The BP230 ELISA is intended for in vitro diagnostic use.
For sale in the EU only. Not for sale in the U.S.
Bullous pemphigoid (BP) is chronic itchy blistering disorder found mainly in aged person, characterized by frequent occurring of tense blister and erythema. IgG anti-basement membrane zone (BMZ) antibodies are found in the serum of patients, and linear IgG or C3 sediment is found on the basement membrane zone of the lesion. Target antigens of the autoantibodies in BP patient serum are BP180 and BP230), also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD respectively. Anti-BP180 is thought to be the pathogenic autoantibody, however, not all BP patients have anti-BP180 antibody in their serum. Anti-BP230 antibody is also highly specific to BP and considered to be a useful serologic marker of the disease.
The MESACUP BP230 TEST has recombinant protein of both N-terminus and C-terminus of BP230 as solid phase and measures anti-BP230 autoantibodies in patient serum specifically.
The MESACUP BP230 TEST is a semi-quantitative enzyme-linked immunosorbent assay (ELISA) for the detection of anti BP230 antibodies in human serum. The BP230 ELISA is intended for in vitro diagnostic use.